Leiah J. Brigitha

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia-A comprehensive review.

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia-A comprehensive review.

Journal: British journal of clinical pharmacology

Published: May 01, 2025

Therapeutic drug monitoring in acute lymphoblastic leukemia-a deep dive into pharmacokinetics, -dynamics, and -genetics of antileukemic drugs.

Therapeutic drug monitoring in acute lymphoblastic leukemia-a deep dive into pharmacokinetics, -dynamics, and -genetics of antileukemic drugs.

Journal: Expert review of clinical pharmacology

Published: February 14, 2025

Implementing Pre-Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects.

Implementing Pre-Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects.

Journal: Clinical pharmacology and therapeutics

Published: January 06, 2025

A Refined Population Pharmacokinetic Model-Based Guideline for Individualized PEGasparaginase Dosing in Pediatric Acute Lymphoblastic Leukemia.

A Refined Population Pharmacokinetic Model-Based Guideline for Individualized PEGasparaginase Dosing in Pediatric Acute Lymphoblastic Leukemia.

Journal: Therapeutic drug monitoring

Published: April 15, 2024

Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized Trial.

Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 02, 2024

Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic Leukemia.

Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic Leukemia.

Journal: Pharmaceutical research

Published: November 10, 2023

Safety of mRNA-based COVID-19 vaccination in paediatric patients with a PEG-asparaginase allergy.

Safety of mRNA-based COVID-19 vaccination in paediatric patients with a PEG-asparaginase allergy.

Journal: EJC paediatric oncology

Published: October 20, 2022

Depletion of d- and l-asparagine in cerebrospinal fluid in acute lymphoblastic leukemia during PEGasparaginase therapy.

Depletion of d- and l-asparagine in cerebrospinal fluid in acute lymphoblastic leukemia during PEGasparaginase therapy.

Journal: Pediatric blood & cancer

Published: March 14, 2022

Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group.

Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 06, 2021

How much asparaginase is needed for optimal outcome in childhood acute lymphoblastic leukaemia? A systematic review.

How much asparaginase is needed for optimal outcome in childhood acute lymphoblastic leukaemia? A systematic review.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 04, 2021

Showing 1-10 of 10

Last Updated: 09/26/2026